FDA Adverse Event Malfunction Summary report: N

INSIGNIA

MDR report key: 3053106 · Received April 11, 2013

Report

Report Number
2124215-2013-04338
Event Type
Malfunction
Date Received
April 11, 2013
Date of Event
May 15, 2008
Report Date
March 7, 2013
Manufacturer
GUIDANT CRM CLONMEL IRELAND
Product Code
NVZ
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

UPON RECEIPT AT OUR POST MARKET QUALITY ASSURANCE LABORATORY, DETAILED MECHANICAL AND ELECTRICAL TESTING WAS PERFORMED ON THE DEVICE. THE DEVICE FUNCTIONED NORMALLY THROUGHOUT TESTING. LABORATORY ANALYSIS DETERMINED THAT THIS DEVICE EXPERIENCED NORMAL BATTERY DEPLETION; HOWEVER, THE ESTIMATED LONGEVITY REMAINING VALUE APPEARED TO DECREASE MORE QUICKLY THAN EXPECTED BETWEEN ROUTINE FOLLOW-UPS. FACTORS INFLUENCING THE ESTIMATED LONGEVITY REMAINING CALCULATION INCLUDE PACING RATE, AMPLITUDE, PULSE-WIDTH AND LEAD IMPEDANCE. ANY (EVEN SLIGHT) CHANGES IN THESE FACTORS WILL IMPACT THE BATTERY CONSUMPTION CALCULATION AND THEREFORE THE REMAINING LONGEVITY ESTIMATE. PLEASE NOTE THAT, DESPITE THE DROP IN ESTIMATED LONGEVITY REMAINING, THE ACTUAL BATTERY CONDITION DID NOT CHANGE SIGNIFICANTLY BETWEEN FOLLOW-UPS. IN SUMMARY, IT WAS DETERMINED THAT THIS DEVICE EXPERIENCED NORMAL BATTERY DEPLETION.

Description of Event or Problem · 1

BOSTON SCIENTIFIC RECEIVED INFORMATION THAT DURING A DEVICE INTERROGATION IT WAS NOTED THAT THE BATTERY LONGEVITY WAS AT THREE AND A HALF YEARS REMAINING. SIX MONTHS AGO THE BATTERY LONGEVITY WAS FIVE YEARS REMAINING. BOSTON SCIENTIFIC TECHNICAL SERVICES (TS) WAS CONSULTED AND PERFORMED A LONGEVITY CALCULATION WHICH SHOWED APPROXIMATELY FOUR YEARS REMAINING LONGEVITY. THE DEVICE WAS EXPLANTED OVER FOUR YEARS LATER FOR REPORTED NORMAL BATTERY DEPLETION. NO ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
154600 INSIGNIA IMPLANTABLE PULSE GENERATOR NVZ GUIDANT CRM CLONMEL IRELAND 1290

Patients

Seq Age Sex Outcome Treatment
1 73 YR 4086| 1290| 4087